- Email: [email protected]
PO002 The clinical, hematological and morphological profile of patients with myelodysplastic syndromes: a single institution experienc
S129
Publication Only
PO001 Smoking is not a risk factor for fungal pneumonia in MDS and AML patients undergoing chemotherapy S. Knipp1 ° , K. Kloft2 , M. Schapira1 , N. Gattermann2 , U. Germing2 . 1 Hematology, CHUV, Lausanne, Switzerland; 2 Hematology, Heinrich-Heine-University, D¨usseldorf, Germany *E-mail: [email protected] Introduction: Fungal pneumonia is a well known and dangerous complication of treatment with intensive chemotherapy in patients suffering from MDS and AML. Smoking is often considered to be a risk factor for developing a fungal infection of the lungs. Patients are proposed to stop smoking during chemotherapy as the risk is considered even higher in patients during aplasia. A correlation between smoking and the development of fungal pneumonia has never been shown, thus we performed this study to investigate correlation between smoking and development of fungal infection of the lungs. Materials and Methods: 411 patients suffering from MDS or AML treated with intensive chemotherapy between 1992 and 2004 at the Department of haematology, university clinics D¨usseldorf, were investigated. Patients were treated with the following chemotherapy-protocols: TAD 9 (Cytarabin 1400 mg/m2 , Daunorubicin 420 mg/m2 and Thioguanin 700 mg/m2 ), HAM (Cytarabin 21000 mg/m2 and Mithoxantron 30 mg/m2 with or without ATRA) and ICE (Idarubicin 36 mg/m2 , VP16 300 mg/m2 and Cytarabin 700 mg/m2 ). Results: Age ranged from 18 to 75 years with a median at 59 years. Of 411 patients, 141 were smokers, 48 were ex-smokers and 187 non-smokers. In 35 cases, smoking-status could not be evaluated. 141 patients (34%) developed fungal pneumonia. Of these patients, 59% (n = 83) were treated with ICE, 28% (n = 39) with HAM and 13% (n = 19) with TAD. 40% of smokers (n = 56) developed fungal pneumonia, 60% (n = 85) did not develop fungal pneumonia. We found similar results when investigating ex-smokers: 44% (n = 21) developed fungal pneumonia, 56% (n = 27) did not develop fungal pneumonia. Of 187 non-smokers, 32% (n = 59) developed fungal pneumonia, 68% (n = 128) did not develop fungal pneumonia. Differences were not statistically significant between the three subgroups (p = n.s.). Conclusion: We could demonstrate that smoking is not a risk factor for developing a fungal pneumonia. Most
patients in this study were non-smokers, never-the-less they developed at least as much fungal infections of the lung as the smokers. The differences between the subgroups smokers, ex-smokers and non-smokers are statistically not different, the difference between the group smokers and exsmokers and the group non-smokers is not different, either.
PO002 The clinical, hematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey F. Demirkan1 , I. Alacacioglu1 ° , G.H. Ozsan1 , O. Piskin1 , B. Akinci2 , M.A. Ozcan1 , T. Yavuzsen3 , E. Yuksel4 , B. Undar1 . 1 Department of Hematology, 2 Department of Internal Medicine, 3 Department of Medical Oncology, 4 Department of Medical Biology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey *E-mail: [email protected] Objective: The main objective of this study was to reclassify our patients with myelodysplastic syndromes (MDS) according to World Health Organisation (WHO) criteria and evaluate prognostic impact of French-AmericanBritish (FAB) and WHO classifications, international prognostic scoring system (IPSS), and other clinical and laboratory variables. Method: One hundred thirteen consecutive series of patients with primary MDS according to FAB classification, diagnosed between December 1992 and December 2005 in our hematology clinic were evaluated retrospectively with clinical and hematological features at diagnosis. Thirtyseven patients were female and seventy-six patient were male (F/M = 37/76). The median age at diagnosis was 69 (range, 33−92). The median follow-up period of all patients was 24 months (1–168 months). According to FAB criteria there were 46 (40.7%) patients with refractory anemia (RA), 9 (8%) with refractory anemia with ring sideroblasts (RARS), 17 (15%) with refractory anemia with excess blasts (RAEB), 4 (3.5%) with refractory anemia with excess blasts in transformation (RAEB-t), and 37 (32.7%) with chronic myelomonocytic leukemia (CMML). IPSS was applied to 75 patients according to FAB (35 RA, 4 RARS, 11 RAEB, 2 RAEB-t, 23 CMML) and to 50 patients according to WHO classification.
Publication Only
PO001 Smoking is not a risk factor for fungal pneumonia in MDS and AML patients undergoing chemotherapy S. Knipp1 ° , K. Kloft2 , M. Schapira1 , N. Gattermann2 , U. Germing2 . 1 Hematology, CHUV, Lausanne, Switzerland; 2 Hematology, Heinrich-Heine-University, D¨usseldorf, Germany *E-mail: [email protected] Introduction: Fungal pneumonia is a well known and dangerous complication of treatment with intensive chemotherapy in patients suffering from MDS and AML. Smoking is often considered to be a risk factor for developing a fungal infection of the lungs. Patients are proposed to stop smoking during chemotherapy as the risk is considered even higher in patients during aplasia. A correlation between smoking and the development of fungal pneumonia has never been shown, thus we performed this study to investigate correlation between smoking and development of fungal infection of the lungs. Materials and Methods: 411 patients suffering from MDS or AML treated with intensive chemotherapy between 1992 and 2004 at the Department of haematology, university clinics D¨usseldorf, were investigated. Patients were treated with the following chemotherapy-protocols: TAD 9 (Cytarabin 1400 mg/m2 , Daunorubicin 420 mg/m2 and Thioguanin 700 mg/m2 ), HAM (Cytarabin 21000 mg/m2 and Mithoxantron 30 mg/m2 with or without ATRA) and ICE (Idarubicin 36 mg/m2 , VP16 300 mg/m2 and Cytarabin 700 mg/m2 ). Results: Age ranged from 18 to 75 years with a median at 59 years. Of 411 patients, 141 were smokers, 48 were ex-smokers and 187 non-smokers. In 35 cases, smoking-status could not be evaluated. 141 patients (34%) developed fungal pneumonia. Of these patients, 59% (n = 83) were treated with ICE, 28% (n = 39) with HAM and 13% (n = 19) with TAD. 40% of smokers (n = 56) developed fungal pneumonia, 60% (n = 85) did not develop fungal pneumonia. We found similar results when investigating ex-smokers: 44% (n = 21) developed fungal pneumonia, 56% (n = 27) did not develop fungal pneumonia. Of 187 non-smokers, 32% (n = 59) developed fungal pneumonia, 68% (n = 128) did not develop fungal pneumonia. Differences were not statistically significant between the three subgroups (p = n.s.). Conclusion: We could demonstrate that smoking is not a risk factor for developing a fungal pneumonia. Most
patients in this study were non-smokers, never-the-less they developed at least as much fungal infections of the lung as the smokers. The differences between the subgroups smokers, ex-smokers and non-smokers are statistically not different, the difference between the group smokers and exsmokers and the group non-smokers is not different, either.
PO002 The clinical, hematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey F. Demirkan1 , I. Alacacioglu1 ° , G.H. Ozsan1 , O. Piskin1 , B. Akinci2 , M.A. Ozcan1 , T. Yavuzsen3 , E. Yuksel4 , B. Undar1 . 1 Department of Hematology, 2 Department of Internal Medicine, 3 Department of Medical Oncology, 4 Department of Medical Biology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey *E-mail: [email protected] Objective: The main objective of this study was to reclassify our patients with myelodysplastic syndromes (MDS) according to World Health Organisation (WHO) criteria and evaluate prognostic impact of French-AmericanBritish (FAB) and WHO classifications, international prognostic scoring system (IPSS), and other clinical and laboratory variables. Method: One hundred thirteen consecutive series of patients with primary MDS according to FAB classification, diagnosed between December 1992 and December 2005 in our hematology clinic were evaluated retrospectively with clinical and hematological features at diagnosis. Thirtyseven patients were female and seventy-six patient were male (F/M = 37/76). The median age at diagnosis was 69 (range, 33−92). The median follow-up period of all patients was 24 months (1–168 months). According to FAB criteria there were 46 (40.7%) patients with refractory anemia (RA), 9 (8%) with refractory anemia with ring sideroblasts (RARS), 17 (15%) with refractory anemia with excess blasts (RAEB), 4 (3.5%) with refractory anemia with excess blasts in transformation (RAEB-t), and 37 (32.7%) with chronic myelomonocytic leukemia (CMML). IPSS was applied to 75 patients according to FAB (35 RA, 4 RARS, 11 RAEB, 2 RAEB-t, 23 CMML) and to 50 patients according to WHO classification.